EU Pharma Strategy Offers Window For Regulatory Optimization
‘Very Significant’ Reforms Offer A Chance To Build On Pandemic Experiences
Executive Summary
Attendees to Medicines for Europe’s Regulatory Affairs and Pharmacovigilance virtual conference heard that a window of opportunity to optimize the region’s regulatory landscape is now “wide open” with the advent of the new EU Pharmaceutical Strategy.
You may also be interested in...
EU Reforms Offer Mixed Blessings For Generics And Biosimilars
A long-awaited package of European pharmaceutical legislation reforms unveiled by the European Commission contains a number of measures that will affect the generics and biosimilars industry – including changes to regulatory data protection periods, simplified marketing authorization procedures, and moves towards greater digitalization.
EU Reforms Offer Mixed Blessings For Generics And Biosimilars
A long-awaited package of European pharmaceutical legislation reforms unveiled by the European Commission contains a number of measures relating to generics and biosimilars – including changes to regulatory data protection periods, simplified marketing authorization procedures and moves towards greater digitalization.
EU ‘Structured Dialog’ Offers Opportunity To Secure Supply
A “structured dialog” led by the European Commission with pharmaceutical industry stakeholders provides a critical opportunity to address weaknesses in the stability and security of the supply chain by improving the environment for local manufacturing, Medicines for Europe believes.